Loading...
Infection is the most common serious adverse event associated with biologic agents that are used to treat rheumatoid arthritis (RA) patients. However, agents vary in their mechanisms of action on the immune system, and whether they confer different risks for infection is unclear. Using Medicare claims data, researchers retrospectively evaluated 31,801 RA patients who received tumor necrosis factor (TNF) inhibitors (etanercept [Enbrel], infliximab [Remicade], adalimumab [Humira], certolizumab [Cimzia], or golimumab [Simponi]) or drugs with other mechanisms of action (abatacept [Orencia], rituximab [Rituxan], or tocilizumab [Actemra]). To ensure that patients in different drug groups were relatively comparable, the study included only patient…